Depression Research

The Mood and Anxiety Disorders Program (MAP) is committed to research that will advance the treatment of depression disorders in a number of areas. Our pharmaceutical studies include exploring novel uses for existing medications such as ketamine (an FDA-approved anesthetic with promising antidepressant effects) and developing new drugs. We are also researching more effective ways to use device-based therapies such as Transcranial Magnetic Stimulation (TMS), in which a magnetic coil is placed against the forehead to stimulate nerves in the brain. Our research into psychotherapy involves studies of new cognitive strategies.

In addition to researching new treatments, MAP is using neuroimaging studies including functional MRI (fMRI) to investigate brain activity during depression in order to better understand the biology of this condition.

Clinical Trials for Depression Disorders

MAP is currently seeking individuals interested in participating in the following clinical trials for depression:

To participate in one of our clinical trials for Mood and Anxiety Disorders or to learn more about eligibility, please contact us (212-241-6539;

Contact Us

Tel: 212-241-6539
Fax: 212-241-3354
Send e-mail

Atran Berg Laboratory Building
Floor E Level
1428 Madison Avenue
New York, NY 10029  Map

Participate in Major Depressive Disorder Clinical Trials

If you are interested in participating, see our current list of depression studies.